ViiV Healthcare v. Hetero USA: Dolutegravir Patent Ends in Consent Judgment
ViiV Healthcare and its co-plaintiffs sued Hetero USA and affiliated Hetero Labs entities in Delaware over US9242986, the patent protecting dolutegravir sodium tablets sold as TIVICAY®. The dispute resolved in just 49 days via a negotiated consent judgment that permanently enjoins Hetero from launching its generic ANDA product without authorisation.
Rapid ANDA settlement locks Hetero out of generic dolutegravir market
On 23 October 2024, ViiV Healthcare Co., Shionogi & Co. Ltd., and ViiV Healthcare UK (No. 3) Limited filed suit against Hetero USA, Inc. and three Hetero Labs Limited entities in the District of Delaware, asserting infringement of US9242986 — a patent covering dolutegravir sodium formulations sold under the TIVICAY® brand. The action arose from Hetero’s ANDA filing seeking approval to market generic dolutegravir sodium tablets at 10 mg and 25 mg base equivalents, triggering the standard Hatch-Waxman 30-month stay mechanism.
The case closed on 11 December 2024, just 49 days after filing, when Judge Mitchell S. Goldberg entered a consent judgment by stipulation of all parties. The judgment permanently enjoins Hetero and its affiliates, successors, and assigns from infringing US9242986 by making, using, selling, importing, or distributing the ANDA product — except as specifically authorised under a private settlement agreement whose commercial terms remain confidential. All claims and counterclaims were dismissed with prejudice, with no costs or fees awarded.
The 49-day resolution is notably swift even by the standards of early ANDA settlements, suggesting the parties entered negotiations promptly after the complaint was filed and that a licensing or launch-date framework was already within reach. The existence of a private settlement agreement — referenced but not published — means the market-entry date and any royalty terms remain undisclosed. It is not publicly known whether Hetero received an authorised generic licence or an agreed launch date in exchange for consenting to the injunction.
Filing to Consent Judgment in 49 days
49-day resolution — unusually fast for Hatch-Waxman ANDA litigation in Delaware
Consent judgment entered: what the injunction and dismissal mean for both sides
Consent judgment is a court-enforceable settlement
A consent judgment is not merely a private contract — it is a court order entered with the full force of judicial authority. By stipulating to entry of judgment, both parties accept the court’s ongoing jurisdiction to supervise and enforce the agreement. Here, the District of Delaware retains jurisdiction to enforce compliance, meaning ViiV can seek contempt sanctions if Hetero launches without authorisation, without needing to file a new lawsuit.
Permanent injunction enteredUS9242986 survives unchallenged; Hetero’s ANDA blocked
Because all claims were dismissed with prejudice under the settlement, Hetero’s invalidity counterclaims — if any were filed or anticipated — are extinguished. US9242986 exits this litigation without any adverse validity finding. ViiV retains full enforceability of the patent against other ANDA filers and third parties. The injunction also binds Hetero’s affiliates and assigns, limiting future workarounds through corporate restructuring.
Patent validity preservedHetero’s generic launch contingent on undisclosed settlement terms
Hetero is permanently enjoined from commercial activity around the ANDA product except as specifically authorised by the settlement agreement. Whether that authorisation takes the form of a future launch date, a royalty-bearing licence, or an authorised generic arrangement is not disclosed in the public record. The with-prejudice dismissal forecloses Hetero from relitigating validity or non-infringement of US9242986 in any future proceeding against ViiV on this ANDA.
Launch terms undisclosedTIVICAY® exclusivity window reinforced across the Hetero entity group
The injunction binds not just Hetero USA but all Hetero Labs affiliates, successors, and assigns — closing the subsidiary loophole sometimes used to circumvent ANDA settlement injunctions. For the broader HIV antiretroviral market, the speed of resolution and breadth of the injunction signals that ViiV is willing to litigate rapidly and settle on favourable terms. Other ANDA filers against US9242986 should anticipate similar enforcement posture from ViiV.
Affiliate-wide injunction scopeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ViiV Healthcare, Co. | Company | Pharmaceutical IP licensor — holder of US9242986 covering dolutegravir (TIVICAY®)Search in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for dolutegravir sodium tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for ViiV Healthcare, Co.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for ViiV Healthcare, Co.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing ViiV Healthcare, Co.Search in Eureka ↗ |
| Defendant counsel | Cortlan S. Hitch | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Mitchell S. Goldberg | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is carefully structured to preserve ViiV’s enforcement leverage while leaving commercially sensitive settlement terms confidential. The injunction is drafted in rem against the ANDA product itself and binds the entire Hetero corporate family — not merely the named defendants. The carve-out phrase ‘except as specifically authorized pursuant to the Settlement Agreement’ is the operative clause for any future authorised generic or negotiated launch: it converts the private settlement into a de facto licence instrument enforceable by contempt proceedings in this court.
US9242986 — dolutegravir sodium HIV integrase inhibitor formulations
US9242986 (application no. US14/272823) protects formulations of dolutegravir sodium, the active ingredient in ViiV’s TIVICAY® tablets, an HIV-1 integrase strand transfer inhibitor (INSTI). Dolutegravir is a cornerstone antiretroviral used in both treatment-naïve and treatment-experienced patients and forms the backbone of several World Health Organisation-preferred HIV regimens. The patent covers the sodium salt form and tablet formulation parameters critical to the commercial product’s bioavailability and stability profile.
As a formulation patent on one of the world’s highest-volume antiretrovirals, US9242986 carries significant commercial weight. TIVICAY® and dolutegravir-containing combination products (including Triumeq® and Dovato®) represent a substantial portion of ViiV’s revenue. Any successful ANDA challenge to this patent would accelerate generic entry into a multi-billion-dollar market segment. The patent’s survival in this litigation — with no validity contest reaching adjudication — reinforces its deterrent value against subsequent Paragraph IV filers targeting the same formulation claims.
Should your R&D or regulatory team run an FTO against US9242986?
Any company developing oral dolutegravir sodium formulations, fixed-dose combination tablets incorporating dolutegravir, or seeking ANDA or 505(b)(2) approval for dolutegravir-based products should treat US9242986 as a primary FTO target. The consent judgment confirmed infringement was not contested to adjudication, suggesting claim scope is commercially significant. Formulation scientists should review excipient selection, salt form, and particle size specifications against the patent’s claims before filing.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US9242986 against your candidate formulation, identify relevant prior art that survived this litigation without being tested, and flag related ViiV and Shionogi patents in the dolutegravir cluster. Eureka’s litigation monitor can also track any new ANDA actions ViiV files against this patent in real time — giving your regulatory and IP team early warning before a 30-month stay is triggered.
Run a freedom-to-operate analysis on US9242986B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: dolutegravir and HIV antiretroviral IP in Delaware
Cases involving Paragraph IV challenges to HIV antiretroviral formulation patents in the District of Delaware — the primary venue for Hatch-Waxman ANDA litigation in the US.
What this case signals for the HIV antiretroviral patent landscape
ViiV’s 49-day resolution demonstrates an aggressive-yet-efficient enforcement strategy for dolutegravir IP that ANDA filers and generic manufacturers should factor into launch planning.
ViiV enforces quickly — generic filers should expect swift injunction exposure
The 49-day cradle-to-consent-judgment timeline suggests ViiV’s litigation team is structured for rapid ANDA enforcement. Generic manufacturers filing ANDAs against dolutegravir formulation patents should assume immediate litigation risk upon paragraph IV certification and plan licence negotiations proactively rather than reactively.
US9242986 exits this case with validity fully intact
No invalidity finding, IPR petition, or claim construction ruling emerged from this action. The with-prejudice dismissal of all counterclaims means the patent’s enforceability against other challengers is, if anything, marginally strengthened — any future litigant faces a clean slate without the benefit of prior art developed here.
ViiV v Hetero — key questions answered
The consent judgment entered 11 December 2024 permanently enjoins Hetero USA, Hetero Labs Limited (all three units), and their affiliates from infringing US9242986 by making, using, selling, importing, or distributing the ANDA dolutegravir product — except as authorised under a private settlement agreement. All claims and counterclaims were dismissed with prejudice. No costs or attorneys’ fees were awarded to either party.
No invalidity finding was made; equally, no validity was formally adjudicated. Because counterclaims were dismissed with prejudice under settlement, Hetero cannot later challenge US9242986 on the same ANDA. The patent exits the case with its enforceability intact, but no court ruling on the merits was issued. Other ANDA filers remain free to mount their own challenges.
Hatch-Waxman ANDA cases in Delaware typically take months to years before any substantive ruling. A 49-day resolution to consent judgment suggests the parties — likely already in pre-litigation contact — reached settlement terms rapidly after the complaint formalised the dispute. This pattern is consistent with a negotiated launch-date or licence framework agreed contemporaneously with ANDA filing.
Possibly, but only if authorised under the terms of the undisclosed settlement agreement. The consent judgment contains an explicit carve-out permitting activities ‘specifically authorized pursuant to the Settlement Agreement.’ The commercial terms — including any agreed launch date or royalty structure — are not part of the public court record.
In ANDA patent settlements, parties routinely keep commercial terms (launch dates, royalties, authorised generic arrangements) confidential. The consent judgment references the settlement agreement as a separate document and incorporates its authorisations by reference, but the agreement itself was not filed on the public docket. FTC reporting requirements under the Medicare Prescription Drug, Improvement, and Modernization Act may require separate disclosure to regulators.
PatSnap Eureka searches patents and litigation data to answer instantly.